{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:17:05Z","timestamp":1770905825510,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Amidst increasing opioid\u2010related overdoses in the USA, opioid use disorder (OUD) treatment has seen few novel treatments emerge. High\u2010potency synthetic opioids (HPSOs) have altered clinical approaches, prompting evaluation of existing medications for opioid use disorder (MOUD) and interest in slow\u2010release oral morphine (SROM) as another therapeutic option. Here we survey addiction specialists on the influence of HPSOs on clinical practice, views on current MOUD regulations, and openness to novel therapies such as SROM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anonymous, online survey conducted at a national conference of addiction specialists (<jats:italic>N<\/jats:italic>\u2009=\u200991). Pearson \u03c7<jats:sup>2<\/jats:sup> tests and Fisher's exact tests to compare respondent characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Approximately 89% of respondents (<jats:italic>N<\/jats:italic>\u2009=\u200991) acknowledge that HPSOs shifted addiction treatment in recent years, with 86% modifying their MOUD prescribing accordingly. Moreover, 84% report having patients who could benefit from other full opioid agonists beyond methadone for OUD management. Many report off\u2010label prescribing of full agonist opioids other than methadone for withdrawal symptoms or initiating MOUD. Eighty percent reported being in favor of incorporating SROM as a third\u2010line monotherapy for OUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>This sample of addiction specialists supports innovative alternatives for MOUD in the USA to combat the challenges posed by fentanyl and related HPSOs. Future work should further addiction specialists' opinions on barriers to OUD treatment and exploration of these international strategies in the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>This appears to be the first study exploring addiction specialists' perspectives on regulatory barriers to OUD treatment and their willingness to uptake internationally adopted strategies such as SROM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.13653","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:04:44Z","timestamp":1728032684000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-7412","authenticated-orcid":false,"given":"Jeremy","family":"Weleff","sequence":"first","affiliation":[{"name":"Department of Psychiatry Faculty of Medicine &amp; Dentistry, University of Alberta Edmonton Alberta Canada"},{"name":"Department of Psychiatry Yale University School of Medicine New Haven Connecticut USA"},{"name":"Neuroscience and Mental Health Institute University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholaus J.","family":"Christian","sequence":"additional","affiliation":[{"name":"Office of the Clinical Director National Institute on Drug Abuse Intramural Research Program, National Institutes of Health Baltimore Maryland USA"},{"name":"Division of Hospital Medicine Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James X.","family":"Wang","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use Vancouver Canada"},{"name":"Division of Adolescent Health and Medicine University of British Columbia Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao P.","family":"De Aquino","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Yale University School of Medicine New Haven Connecticut USA"},{"name":"VA Connecticut Healthcare System West Haven Connecticut USA"},{"name":"Clinical Neuroscience Research Unit Connecticut Mental Health Center New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences University of Washington School of Medicine Seattle Washington USA"},{"name":"Center for Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Garcia","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Yale University School of Medicine New Haven Connecticut USA"},{"name":"VA Connecticut Healthcare System West Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Provisional drug overdose death counts","author":"Ahmad FB","year":"2024"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16318"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000952"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00145-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1300\/J023v01n01_01"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025799"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02334.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00190-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2020.06.004"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.05.012"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12440"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108350"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13365"},{"issue":"6","key":"e_1_2_8_15_1","article-title":"Slow\u2010release oral morphine as maintenance therapy for opioid dependence","author":"Ferri M","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_16_1","unstructured":"BCCSU.A Guideline for the Clinical Management of Opioid Use Disorder 2023 Update. British Columbia Centre on Substance Use and B.C. Ministry of Health; 2023.https:\/\/www.bccsu.ca\/wp-content\/uploads\/2023\/12\/BC-OUD-Treatment-Guideline_2023-Update.pdf"},{"key":"e_1_2_8_17_1","volume-title":"Methadone Treatment for People Who Use Fentanyl: Recommendations","author":"Bromley L","year":"2021"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CXA.0000000000000072"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03923.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.09.003"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_2_8_23_1","unstructured":"Drug Enforcement Administration Department of Justice.21 CFR Part 1306 Dispensing of Narcotic Drugs To Relieve Acute Withdrawal Symptoms of Opioid Use Disorder;2023."},{"key":"e_1_2_8_24_1","unstructured":"Drug Enforcement Administration Department of Justice. \u00a7 1306.07Administering or Dispensing of Narcotic Drugs.https:\/\/www.ecfr.gov\/current\/title-21\/part-1306\/section-1306.07"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.8111"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00368-z"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab129"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.003"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2015.1035835"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","unstructured":"PeprahK LoshakH Cost\u2010Effectiveness and Guidelines for Opioid Substitution Treatment: CADTH Health Technology Review. Canadian Agency for Drugs and Technologies in Health; 2021.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK591054\/","DOI":"10.51731\/cjht.2021.230"},{"key":"e_1_2_8_31_1","unstructured":"U.S. Food and Drug Administration.Framework for FDA's Real\u2010World Evidence Program.2018."}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T12:26:43Z","timestamp":1735302403000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/ajad.13653"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13653","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"2024-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}